Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials

David L. Paterson

DOI: https://doi.org/10.1080/13543784.2024.2326028

2024-03-07

Expert Opinion on Investigational Drugs

Abstract:Introduction Antimicrobial resistance is a major threat to modern healthcare, and it is often regarded that the antibiotic pipeline is 'dry.'

pharmacology & pharmacy

What problem does this paper attempt to address?

Critical analysis of antibacterial agents in clinical development

Ursula Theuretzbacher,Karen Bush,Stephan Harbarth,Mical Paul,John H. Rex,Evelina Tacconelli,Guy E. Thwaites

DOI: https://doi.org/10.1038/s41579-020-0340-0

IF: 88.1

2020-03-09

Nature Reviews Microbiology

Abstract:The antibacterial agents currently in clinical development are predominantly derivatives of well-established antibiotic classes and were selected to address the class-specific resistance mechanisms and determinants that were known at the time of their discovery. Many of these agents aim to target the antibiotic-resistant priority pathogens listed by the WHO, including Gram-negative bacteria in the critical priority category, such as carbapenem-resistant <i>Acinetobacter</i>, <i>Pseudomonas</i> and Enterobacterales. Although some current compounds in the pipeline have exhibited increased susceptibility rates in surveillance studies that depend on geography, pre-existing cross-resistance both within and across antibacterial classes limits the activity of many of the new agents against the most extensively drug-resistant (XDR) and pan-drug-resistant (PDR) Gram-negative pathogens. In particular, cross-resistance to unrelated classes may occur by co-selection of resistant strains, thus leading to the rapid emergence and subsequent spread of resistance. There is a continued need for innovation and new-class antibacterial agents in order to provide effective therapeutic options against infections specifically caused by XDR and PDR Gram-negative bacteria.

microbiology
Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It

Zeinab Breijyeh,Buthaina Jubeh,Rafik Karaman

DOI: https://doi.org/10.3390/molecules25061340

IF: 4.6

2020-03-16

Molecules

Abstract:Antimicrobial resistance represents an enormous global health crisis and one of the most serious threats humans face today. Some bacterial strains have acquired resistance to nearly all antibiotics. Therefore, new antibacterial agents are crucially needed to overcome resistant bacteria. In 2017, the World Health Organization (WHO) has published a list of antibiotic-resistant priority pathogens, pathogens which present a great threat to humans and to which new antibiotics are urgently needed the list is categorized according to the urgency of need for new antibiotics as critical, high, and medium priority, in order to guide and promote research and development of new antibiotics. The majority of the WHO list is Gram-negative bacterial pathogens. Due to their distinctive structure, Gram-negative bacteria are more resistant than Gram-positive bacteria, and cause significant morbidity and mortality worldwide. Several strategies have been reported to fight and control resistant Gram-negative bacteria, like the development of antimicrobial auxiliary agents, structural modification of existing antibiotics, and research into and the study of chemical structures with new mechanisms of action and novel targets that resistant bacteria are sensitive to. Research efforts have been made to meet the urgent need for new treatments; some have succeeded to yield activity against resistant Gram-negative bacteria by deactivating the mechanism of resistance, like the action of the β-lactamase Inhibitor antibiotic adjuvants. Another promising trend was by referring to nature to develop naturally derived agents with antibacterial activity on novel targets, agents such as bacteriophages, DCAP(2-((3-(3,6-dichloro-9H-carbazol-9-yl)-2-hydroxypropyl)amino)-2(hydroxymethyl)propane1,3-diol, Odilorhabdins (ODLs), peptidic benzimidazoles, quorum sensing (QS) inhibitors, and metal-based antibacterial agents.

chemistry, multidisciplinary,biochemistry & molecular biology
Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps

Valeria Gigante,Richard A Alm,Daniela Melchiorri,Tamarie Rocke,Cesar A Arias,Lloyd Czaplewski,Prabhavathi Fernandes,François Franceschi,Stephan Harbarth,Roman Kozlov,Christian Lienhardt,Norio Ohmagari,Lesley A Ogilvie,Mical Paul,John H Rex,Lynn L Silver,Melvin Spigelman,Hatim Sati,Alexandra M Cameron

DOI: https://doi.org/10.1128/aac.00535-24

2024-08-07

Abstract:Antimicrobial resistance (AMR) is a major global health threat estimated to have caused the deaths of 1.27 million people in 2019, which is more than HIV/AIDS and malaria deaths combined. AMR also has significant consequences on the global economy. If not properly addressed, AMR could immensely impact the world's economy, further increasing the poverty burden in low- and middle-income countries. To mitigate the risk of a post-antibiotic society, where the ability to effectively treat common bacterial infections is being severely threatened, it is necessary to establish a continuous supply of new and novel antibacterial medicines. However, there are gaps in the current pipeline that will prove difficult to address, given the time required to develop new agents. To understand the status of upstream antibiotic development and the challenges faced by drug developers in the early development stage, the World Health Organization has regularly assessed the preclinical and clinical antibacterial development pipeline. The review identifies potential new classes of antibiotics or novel mechanisms of action that can better address resistant bacterial strains. This proactive approach is necessary to stay ahead of evolving resistance patterns and to support the availability of effective treatment options. This review examines the trends in preclinical development and attempts to identify gaps and potential opportunities to overcome the numerous hurdles in the early stages of the antibacterial research and development space.
Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed

C. Lienhardt,Laila Al-Sulaiman,Hatim F Sati,J. Rex,M. Butler,V. Gigante,S. Harbarth,L. Silver,Peter Beyer,P. Fernandes,R. Alm,N. Ohmagari,M. Paul,S. Paulin,L. Czaplewski,G. Thwaites,C. Arias,M. Spigelman,R. Kozlov

DOI: https://doi.org/10.1128/aac.01991-21

IF: 5.938

2022-01-10

Antimicrobial Agents and Chemotherapy

Abstract:There is an urgent global need for new strategies and drugs to control and treat multidrug-resistant bacterial infections. In 2017, the World Health Organization (WHO) released a list of 12 antibiotic-resistant priority pathogens and began to critically analyze the antibacterial clinical pipeline. This review analyzes “traditional” and “nontraditional” antibacterial agents and modulators in clinical development current on 30 June 2021 with activity against the WHO priority pathogens mycobacteria and Clostridioides difficile. ABSTRACT There is an urgent global need for new strategies and drugs to control and treat multidrug-resistant bacterial infections. In 2017, the World Health Organization (WHO) released a list of 12 antibiotic-resistant priority pathogens and began to critically analyze the antibacterial clinical pipeline. This review analyzes “traditional” and “nontraditional” antibacterial agents and modulators in clinical development current on 30 June 2021 with activity against the WHO priority pathogens mycobacteria and Clostridioides difficile. Since 2017, 12 new antibacterial drugs have been approved globally, but only vaborbactam belongs to a new antibacterial class. Also innovative is the cephalosporin derivative cefiderocol, which incorporates an iron-chelating siderophore that facilitates Gram-negative bacteria cell entry. Overall, there were 76 antibacterial agents in clinical development (45 traditional and 31 nontraditional), with 28 in phase 1, 32 in phase 2, 12 in phase 3, and 4 under regulatory evaluation. Forty-one out of 76 (54%) targeted WHO priority pathogens, 16 (21%) were against mycobacteria, 15 (20%) were against C. difficile, and 4 (5%) were nontraditional agents with broad-spectrum effects. Nineteen of the 76 antibacterial agents have new pharmacophores, and 4 of these have new modes of actions not previously exploited by marketed antibacterial drugs. Despite there being 76 antibacterial clinical candidates, this analysis indicated that there were still relatively few clinically differentiated antibacterial agents in late-stage clinical development, especially against critical-priority pathogens. We believe that future antibacterial research and development (R&D) should focus on the development of innovative and clinically differentiated candidates that have clear and feasible progression pathways to the market.

Medicine
New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives

Marco Terreni,Marina Taccani,Massimo Pregnolato

DOI: https://doi.org/10.3390/molecules26092671

IF: 4.6

2021-05-02

Molecules

Abstract:The present work aims to examine the worrying problem of antibiotic resistance and the emergence of multidrug-resistant bacterial strains, which have now become really common in hospitals and risk hindering the global control of infectious diseases. After a careful examination of these phenomena and multiple mechanisms that make certain bacteria resistant to specific antibiotics that were originally effective in the treatment of infections caused by the same pathogens, possible strategies to stem antibiotic resistance are analyzed. This paper, therefore, focuses on the most promising new chemical compounds in the current pipeline active against multidrug-resistant organisms that are innovative compared to traditional antibiotics: Firstly, the main antibacterial agents in clinical development (Phase III) from 2017 to 2020 are listed (with special attention on the treatment of infections caused by the pathogens Neisseria gonorrhoeae, including multidrug-resistant isolates, and Clostridium difficile), and then the paper moves on to the new agents of pharmacological interest that have been approved during the same period. They include tetracycline derivatives (eravacycline), fourth generation fluoroquinolones (delafloxacin), new combinations between one β-lactam and one β-lactamase inhibitor (meropenem and vaborbactam), siderophore cephalosporins (cefiderocol), new aminoglycosides (plazomicin), and agents in development for treating drug-resistant TB (pretomanid). It concludes with the advantages that can result from the use of these compounds, also mentioning other approaches, still poorly developed, for combating antibiotic resistance: Nanoparticles delivery systems for antibiotics.

chemistry, multidisciplinary,biochemistry & molecular biology
Novel antibacterial agents for the treatment of serious Gram-positive infections

Darren Abbanat,Mark Macielag,Karen Bush

DOI: https://doi.org/10.1517/13543784.12.3.379

Abstract:With the continuing development of clinical drug resistance among bacteria and the advent of resistance to the recently released agents quinupristin-dalfopristin and linezolid, the need for new, effective agents to treat multi-drug-resistant Gram-positive infections remains important. This review focuses on agents presently in clinical development for the treatment of serious multidrug-resistant staphylococcal, enterococcal and pneumococcal infections, including methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci and penicillin-resistant Streptococcus pneumoniae. Agents to be discussed that affect the prokaryotic cell wall include the antimethicillin-resistant S. aureus cephalosporins BAL9141 and RWJ-54428, the glycopeptides oritavancin and dalbavancin and the lipopeptide daptomycin. Topoisomerase inhibitors include the fluoroquinolones gemifloxacin, sitafloxacin and garenoxacin. Protein synthesis inhibitors are represented by the ketolides telithromycin and cethromycin, the oxazolidinones and the glycylcycline tigecycline. Although each of these compounds has demonstrated antibacterial activity against antibiotic-resistant pathogens, their final regulatory approval will depend on an acceptable clinical safety profile.
Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research

Roderich Süssmuth,Marcel David Kulike-Koczula,Peng Gao,Simone Kosol

DOI: https://doi.org/10.1002/anie.202414325

2024-11-30

Angewandte Chemie International Edition

Abstract:In the fight against bacterial infections, particularly those caused by multi-resistant pathogens, the need for new antibacterials is undoubted in scientific communities. and is by now also widely perceived by the general population. However, the antibacterial research landscape has changed considerably over the past years. The majority of big pharma companies has left the field and thus, the decline in R&D on antibacterials severely impacts the drug pipeline. In past years, antibacterial research increasingly relies on smaller companies or academic research institutions, which mostly have only limited financial resources, to carry a drug discovery and development process from the beginning and through the clinical phases. This review formulates the requirements for an antibacterial in regard of targeted pathogens and resistance mechanisms. Strategies are shown for the discovery of new antibacterial structures originating from natural sources, chemical synthesis and more recent AI approaches. This is complemented by principles for the computer-aided design of antibacterials and the refinement of a lead structure. The second part of the article comprises a compilation of promising antibacterial molecules classified according to bacterial target areas. Aspects of the origin, the antibacterial spectrum, resistance and the current development status of the presented drug molecules are highlighted.

chemistry, multidisciplinary
The Science of Antibiotic Discovery

Kim Lewis

DOI: https://doi.org/10.1016/j.cell.2020.02.056

IF: 64.5

2020-04-01

Cell

Abstract:We are experiencing an antimicrobial resistance (AMR) crisis, brought on by the drying up of the antibiotic discovery pipeline and the resulting unchecked spread of resistant pathogens. Traditional methods of screening environmental isolates or compound libraries have not produced a new drug in over 30 years. Antibiotic discovery is uniquely difficult due to a highly restrictive penetration barrier and other mechanisms that allow bacteria to survive in the presence of toxic compounds. In this Perspective, we analyze the challenges facing discovery and discuss an emerging new platform for antibiotic discovery. The penetration barrier makes screening conventional synthetic compound libraries largely impractical, and actinomycetes, the main source of natural product compounds, have been overmined. The emerging platform is based on understanding the rules that guide the permeation of molecules into bacteria and on advances in microbiology, which enable us to identify and access attractive groups of secondary metabolite producers. Establishing this platform will enable reliable production of lead compounds to combat AMR.

cell biology,biochemistry & molecular biology
Antibiotic Development: Lessons from the Past and Future Opportunities

Michael S. Kinch,Zachary Kraft,Tyler Schwartz

DOI: https://doi.org/10.1007/s11095-024-03694-2

IF: 4.58

2024-04-03

Pharmaceutical Research

Abstract:The challenge of antimicrobial resistance is broadly appreciated by the clinical and scientific communities. To assess progress in the development of medical countermeasures to combat bacterial infections, we deployed information gleaned from clinical trials conducted from 2000 to 2021. Whereas private sector interest in cancer grew dramatically over this period, activity to combat bacterial infections remained stagnant. The comparative ambivalence to antimicrobial resistance is reflected in the number of investigative drugs under clinical investigation, their stage of development and most troublingly, a declining number of organizations that are actively involved in the development of new products to treat bacterial infections. This drop reflects the exits of many companies that had previously developed antibacterial agents.

pharmacology & pharmacy,chemistry, multidisciplinary
Antibiotic Potentiators Against Multidrug-Resistant Bacteria: Discovery, Development, and Clinical Relevance

Meenal Chawla,Jyoti Verma,Rashi Gupta,Bhabatosh Das

DOI: https://doi.org/10.3389/fmicb.2022.887251

IF: 5.2

2022-07-02

Frontiers in Microbiology

Abstract:Antimicrobial resistance in clinically important microbes has emerged as an unmet challenge in global health. Extensively drug-resistant bacterial pathogens have cropped up lately defying the action of even the last resort of antibiotics. This has led to a huge burden in the health sectors and increased morbidity and mortality rate across the world. The dwindling antibiotic discovery pipeline and rampant usage of antibiotics has set the alarming bells necessitating immediate actions to combat this looming threat. Various alternatives to discovery of new antibiotics are gaining attention such as reversing the antibiotic resistance and hence reviving the arsenal of antibiotics in hand. Antibiotic resistance reversal is mainly targeted against the antibiotic resistance mechanisms, which potentiates the effective action of the antibiotic. Such compounds are referred to as resistance breakers or antibiotic adjuvants/potentiators that work in conjunction with antibiotics. Many studies have been conducted for the identification of compounds, which decrease the permeability barrier, expression of efflux pumps and the resistance encoding enzymes. Compounds targeting the stability, inheritance and dissemination of the mobile genetic elements linked with the resistance genes are also potential candidates to curb antibiotic resistance. In pursuit of such compounds various natural sources and synthetic compounds have been harnessed. The activities of a considerable number of compounds seem promising and are currently at various phases of clinical trials. This review recapitulates all the studies pertaining to the use of antibiotic potentiators for the reversal of antibiotic resistance and what the future beholds for their usage in clinical settings.

microbiology
New Agents Are Coming, and so Is the Resistance

J. Myles Keck,Alina Viteri,Jacob Schultz,Rebecca Fong,Charles Whitman,Madeline Poush,Marlee Martin

DOI: https://doi.org/10.3390/antibiotics13070648

2024-07-14

Antibiotics

Abstract:Antimicrobial resistance is a global threat that requires urgent attention to slow the spread of resistant pathogens. The United States Centers for Disease Control and Prevention (CDC) has emphasized clinician-driven antimicrobial stewardship approaches including the reporting and proper documentation of antimicrobial usage and resistance. Additional efforts have targeted the development of new antimicrobial agents, but narrow profit margins have hindered manufacturers from investing in novel antimicrobials for clinical use and therefore the production of new antibiotics has decreased. In order to combat this, both antimicrobial drug discovery processes and healthcare reimbursement programs must be improved. Without action, this poses a high probability to culminate in a deadly post-antibiotic era. This review will highlight some of the global health challenges faced both today and in the future. Furthermore, the new Infectious Diseases Society of America (IDSA) guidelines for resistant Gram-negative pathogens will be discussed. This includes new antimicrobial agents which have gained or are likely to gain FDA approval. Emphasis will be placed on which human pathogens each of these agents cover, as well as how these new agents could be utilized in clinical practice.

pharmacology & pharmacy,infectious diseases
Evaluation of Antibiotic Resistance Mechanisms in Gram-Negative Bacteria

Anusha Gauba,Khondaker Miraz Rahman

DOI: https://doi.org/10.3390/antibiotics12111590

2023-11-04

Antibiotics

Abstract:Multidrug-resistant Gram-negative bacterial infections are exponentially increasing, posing one of the most urgent global healthcare and economic threats. Due to the lack of new therapies, the World Health Organization classified these bacterial species as priority pathogens in 2017, known as ESKAPE pathogens. This classification emphasizes the need for urgent research and development of novel targeted therapies. The majority of these priority pathogens are Gram-negative species, which possess a structurally dynamic cell envelope enabling them to resist multiple antibiotics, thereby leading to increased mortality rates. Despite 6 years having passed since the WHO classification, the progress in generating new treatment ideas has not been sufficient, and antimicrobial resistance continues to escalate, acting as a global ticking time bomb. Numerous efforts and strategies have been employed to combat the rising levels of antibiotic resistance by targeting specific resistance mechanisms. These mechanisms include antibiotic inactivating/modifying enzymes, outer membrane porin remodelling, enhanced efflux pump action, and alteration of antibiotic target sites. Some strategies have demonstrated clinical promise, such as the utilization of beta-lactamase inhibitors as antibiotic adjuvants, as well as recent advancements in machine-based learning employing artificial intelligence to facilitate the production of novel narrow-spectrum antibiotics. However, further research into an enhanced understanding of the precise mechanisms by which antibiotic resistance occurs, specifically tailored to each bacterial species, could pave the way for exploring narrow-spectrum targeted therapies. This review aims to introduce the key features of Gram-negative bacteria and their current treatment approaches, summarizing the major antibiotic resistance mechanisms with a focus on Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Additionally, potential directions for alternative therapies will be discussed, along with their relative modes of action, providing a future perspective and insight into the discipline of antimicrobial resistance.

pharmacology & pharmacy,infectious diseases
Antibacterial Prodrugs to Overcome Bacterial Antimicrobial Resistance

Catarina Maria,Ana M. de Matos,Amélia P. Rauter

DOI: https://doi.org/10.3390/ph17060718

IF: 4.6

2024-06-02

Pharmaceuticals

Abstract:Antimicrobial resistance (AMR) is an increasingly concerning phenomenon that requires urgent attention because it poses a threat to human and animal health. Bacteria undergo continuous evolution, acquiring novel resistance mechanisms in addition to their intrinsic ones. Multidrug-resistant and extensively drug-resistant bacterial strains are rapidly emerging, and it is expected that bacterial AMR will claim the lives of 10 million people annually by 2050. Consequently, the urgent need for the development of new therapeutic agents with new modes of action is evident. The antibacterial prodrug approach, a strategy that includes drug repurposing and derivatization, integration of nanotechnology, and exploration of natural products, is highlighted in this review. Thus, this publication aims at compiling the most pertinent research in the field, spanning from 2021 to 2023, offering the reader a comprehensive insight into the AMR phenomenon and new strategies to overcome it.

pharmacology & pharmacy,chemistry, medicinal
New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians

Davide Carcione,Jari Intra,Lilia Andriani,Floriana Campanile,Floriana Gona,Silvia Carletti,Nicasio Mancini,Gioconda Brigante,Dario Cattaneo,Sara Baldelli,Mattia Chisari,Alessandra Piccirilli,Stefano Di Bella,Luigi Principe

DOI: https://doi.org/10.3390/ph16091304

2023-09-15

Abstract:Antibiotic resistance is a public health problem with increasingly alarming data being reported. Gram-positive bacteria are among the protagonists of severe nosocomial and community infections. The objective of this review is to conduct an extensive examination of emerging treatments for Gram-positive infections including ceftobiprole, ceftaroline, dalbavancin, oritavancin, omadacycline, tedizolid, and delafloxacin. From a methodological standpoint, a comprehensive analysis on clinical trials, molecular structure, mechanism of action, microbiological targeting, clinical use, pharmacokinetic/pharmacodynamic features, and potential for therapeutic drug monitoring will be addressed. Each antibiotic paragraph is divided into specialized microbiological, clinical, and pharmacological sections, including detailed and appropriate tables. A better understanding of the latest promising advances in the field of therapeutic options could lead to the development of a better approach in managing antimicrobial therapy for multidrug-resistant Gram-positive pathogens, which increasingly needs to be better stratified and targeted.
Advances on the research and development of new antimicrobial agents

WANG Ming-Gui

DOI: https://doi.org/10.3969/j.issn.1673-6184.2012.01.003

2012-01-01

Abstract:Bacterial resistance to antimicrobials has been a global problem. On the other hand, however, the development of new antimicrobials has been markedly decreased since 1990s. We are facing the situation that there will be no drug to be used for the treatment of severe infections caused by pan-drug resistant bacteria. To date, some new compounds or new drugs which are active against multi-drug resistant bacteria, have been developed in recent years, and are at different phases of clinical trials. This review includes three recently U.S. Food and Drug Administration (FDA) approved drugs (Telavancin, Ceftaroline and Fidaxomicin), Tigecyline which has been launched in China at the end of 2011, and several new antimicrobials at phases I to III clinical trials.
Beyond Antibiotics: What the Future Holds

Payam Benyamini

DOI: https://doi.org/10.3390/antibiotics13100919

2024-09-26

Antibiotics

Abstract:The prevalence of multidrug resistance (MDR) and stagnant drug-development pipelines have led to the rapid rise of hard-to-treat antibiotic-resistant bacterial infections. These infectious diseases are no longer just nosocomial but are also becoming community-acquired. The spread of MDR has reached a crisis level that needs immediate attention. The landmark O'Neill report projects that by 2050, mortality rates associated with MDR bacterial infections will surpass mortality rates associated with individuals afflicted with cancer. Since conventional antimicrobials are no longer very reliable, it is of great importance to investigate different strategies to combat these life-threatening infectious diseases. Here, we provide an overview of recent advances in viable alternative treatment strategies mainly targeting a pathogen's virulence capability rather than viability. Topics include small molecule and immune inhibition of virulence factors, quorum sensing (QS) quenching, inhibition of biofilm development, bacteriophage-mediated therapy, and manipulation of an individual's macroflora to combat MDR bacterial infections.

pharmacology & pharmacy,infectious diseases
The Quest for Novel Antimicrobial Compounds: Emerging Trends in Research, Development, and Technologies

Pavan Mantravadi,Karunakaran Kalesh,Renwick Dobson,André Hudson,Anutthaman Parthasarathy

DOI: https://doi.org/10.3390/antibiotics8010008

2019-01-24

Antibiotics

Abstract:Pathogenic antibiotic resistant bacteria pose one of the most important health challenges of the 21st century. The overuse and abuse of antibiotics coupled with the natural evolutionary processes of bacteria has led to this crisis. Only incremental advances in antibiotic development have occurred over the last 30 years. Novel classes of molecules, such as engineered antibodies, antibiotic enhancers, siderophore conjugates, engineered phages, photo-switchable antibiotics, and genome editing facilitated by the CRISPR/Cas system, are providing new avenues to facilitate the development of antimicrobial therapies. The informatics revolution is transforming research and development efforts to discover novel antibiotics. The explosion of nanotechnology and micro-engineering is driving the invention of antimicrobial materials, enabling the cultivation of “uncultivable” microbes and creating specific and rapid diagnostic technologies. Finally, a revival in the ecological aspects of microbial disease management, the growth of prebiotics, and integrated management based on the “One Health” model, provide additional avenues to manage this health crisis. These, and future scientific and technological developments, must be coupled and aligned with sound policy and public awareness to address the risks posed by rising antibiotic resistance.
Newer antibacterial drugs for a new century

Gina Devasahayam,William M Scheld,Paul S Hoffman

DOI: https://doi.org/10.1517/13543780903505092

2010-01-07

Expert Opinion on Investigational Drugs

Abstract:IMPORTANCE OF THE FIELD: Antibacterial drug discovery and development has slowed considerably in recent years, with novel classes discovered decades ago and regulatory approvals tougher to get. Traditional approaches and the newer genomic mining approaches have not yielded novel classes of antibacterial compounds. Instead, improved analogues of existing classes of antibacterial drugs have been developed by improving potency, minimizing resistance and alleviating toxicity.AREAS COVERED IN THIS REVIEW: This article is a comprehensive review of newer classes of antibacterial drugs introduced or approved after year 2000.WHAT THE READER WILL GAIN: It describes their mechanisms of action/resistance, improved analogues, spectrum of activity and clinical trials. It also discusses new compounds in development with novel mechanisms of action, as well as novel unexploited bacterial targets and strategies that may pave the way for combating drug resistance and emerging pathogens in the twenty-first century.TAKE HOME MESSAGE: The outlook of antibacterial drug discovery, though challenging, may not be insurmountable in the years ahead, with legislation on incentives and funding introduced for developing an antimicrobial discovery program and efforts to conserve antibacterial drug use.

pharmacology & pharmacy
Friends or foes? Novel antimicrobials tackling MDR/XDR Gram-negative bacteria: a systematic review

Mihai Octavian Dan,Daniela Tǎlǎpan

DOI: https://doi.org/10.3389/fmicb.2024.1385475

IF: 5.2

2024-05-11

Frontiers in Microbiology

Abstract:Systematic review registration: Gram-negative bacteria have been one of the most studied classes in the field of microbiology, especially in the context of globally alarming antimicrobial resistance levels to these pathogens over the course of the past decades. With high numbers of these microorganisms being described as multidrug-resistant (MDR), or even extended-drug-resistant (XDR) bacteria, specialists in the field have been struggling to keep up with higher prevalence of difficult-to-treat infections caused by such superbugs. The FDA approval of novel antimicrobials, such as cefiderocol (FDC), ceftolozane/tazobactam (C/T), ceftazidime/avibactam (CZA), imipenem/relebactam (IMR), sulbactam/durlobactam (SUL-DUR) and phase 3 clinical trials' results of aztreonam/avibactam (ATM-AVI) has proven that, while all these substances provide encouraging efficacy rates, antibiotic resistance keeps up with the pace of drug development. Microorganisms have developed more extensive mechanisms of resistance in order to target the threat posed by these novel antimicrobials, thus equiring researchers to be on a constant lookout for other potential drug candidates and molecule development. However, these strategies require a proper understanding of bacterial resistance mechanisms to gain a comprehensive outlook on the issue. The present review aims to highlight these six antibiotic agents, which have brought hope to clinicians during the past decade, discussing general properties of these substances, as well as mechanisms and patterns of resistance, while also providing a short overview on further directions in the field. https://www.crd.york.ac.uk/prospero/#searchadvanced, Identifier CRD42024505832.

microbiology
Antimicrobial Properties on Non-Antibiotic Drugs in the Era of Increased Bacterial Resistance

Maria Lagadinou,Maria Octavia Onisor,Athanasios Rigas,Daniel-Vasile Musetescu,Despoina Gkentzi,Stelios F. Assimakopoulos,George Panos,Markos Marangos

DOI: https://doi.org/10.3390/antibiotics9030107

2020-03-02

Antibiotics

Abstract:In recent years, due to the dramatic increase in and global spread of bacterial resistance to a number of commonly used antibacterial agents, many studies have been directed at investigating drugs whose primary therapeutic purpose is not antimicrobial action. In an era where it is becoming increasingly difficult to find new antimicrobial drugs, it is important to understand these antimicrobial effects and their potential clinical implications. Numerous studies report the antibacterial activity of non-steroidal anti-inflammatory drugs, local anaesthetics, phenothiazines such as chlorpromazine, levomepromazine, promethazine, trifluoperazine, methdilazine and thioridazine, antidepressants, antiplatelets and statins. Several studies have explored a possible protective effect of statins inreducing the morbidity and mortality of many infectious diseases. Various non-antibiotic agents exhibit antimicrobial activity via multiple and different mechanisms of action. Further studies are required in the field to further investigate these antimicrobial properties in different populations. This is of paramount importance in the antimicrobial resistance era, where clinicians have limited therapeutic options to combat problematic infections.

Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials

Critical analysis of antibacterial agents in clinical development

Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It

Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps

Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed

New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives

Novel antibacterial agents for the treatment of serious Gram-positive infections

Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research

The Science of Antibiotic Discovery

Antibiotic Development: Lessons from the Past and Future Opportunities

Antibiotic Potentiators Against Multidrug-Resistant Bacteria: Discovery, Development, and Clinical Relevance

New Agents Are Coming, and so Is the Resistance

Evaluation of Antibiotic Resistance Mechanisms in Gram-Negative Bacteria

Antibacterial Prodrugs to Overcome Bacterial Antimicrobial Resistance

New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians

Advances on the research and development of new antimicrobial agents

Beyond Antibiotics: What the Future Holds

The Quest for Novel Antimicrobial Compounds: Emerging Trends in Research, Development, and Technologies

Newer antibacterial drugs for a new century

Friends or foes? Novel antimicrobials tackling MDR/XDR Gram-negative bacteria: a systematic review

Antimicrobial Properties on Non-Antibiotic Drugs in the Era of Increased Bacterial Resistance